Neovacs SA of France is set to start a Phase 2 trial of its active immunotherapy in patients with Crohn’s disease. This follows an earlier study in Crohn’s that elicited an antibody response where nearly half the patients achieved disease remission.
Neovacs SA of France is set to start a Phase 2 trial of its active immunotherapy in patients with Crohn’s disease. This follows an earlier study in Crohn’s that elicited an antibody response where nearly half the patients achieved disease remission.